BioVie Inc - Class A

Research BioVie Inc - Class A (BIVI) on Bullrun: market cap USD 15.16M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBIVI
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 15.16M
• Financial periodFY2025
• Net income-USD 17.54M

Valuation Snapshot

latest market cap is USD 15.16M.

About BioVie Inc - Class A

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease;

Frequently asked questions

What is BioVie Inc - Class A's market cap?

BioVie Inc - Class A's market capitalization is USD 15.16M.

What does BioVie Inc - Class A do?

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.